13 Geographic Atrophy Clinical Trials in Sacramento, CA (2026)

Q: How do I join a clinical trial in Sacramento?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you.

Recruiting Geographic Atrophy Studies in Sacramento

NCT00358943Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatme...

Sacramento, CA12,000 participantsGenzyme, a Sanofi Company

View Study Details

NCT05219110Recruiting

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E...

Sacramento, CANA1,040 participantsUniversity of Calgary

View Study Details

NCT06103864Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...

Sacramento, CAPHASE3625 participantsAstraZeneca

View Study Details

NCT06659445Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients wi...

Sacramento, CAPHASE2324 participantsONL Therapeutics

View Study Details

NCT07260916Recruiting

Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation

MINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to eit...

Sacramento, CANA300 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT07441642Recruiting

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)....

Sacramento, CAPHASE2272 participantsNovartis Pharmaceuticals

View Study Details

NCT07215234Recruiting

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) seco...

Sacramento, CAPHASE1104 participantsSanofi

View Study Details

NCT07425574Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular d...

Sacramento, CA90 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07199465Recruiting

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the stu...

Sacramento, CAPHASE140 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04422912Recruiting

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-...

Sacramento, CAPHASE140 participantsCabaletta Bio

View Study Details

NCT07544251Recruiting

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

This study is being done to help better understand how the gut and skin bacteria of the body change when people with acne are treated with Sarecycline or Doxycycline. The bacteria in the gut and on th...

Sacramento, CAPHASE430 participantsIntegrative Skin Science and Research

View Study Details

NCT06878950Recruiting

Early Feeds in Gastroschisis

This study aims to evaluate the feasibility of initiating early feeds in neonates with gastroschisis, a condition where infants are born with their intestines outside the body....

Sacramento, CANA20 participantsUniversity of California, Davis

View Study Details

NCT07594236Recruiting

Phase 1 Study of C.001 in Retinal Degeneration

This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium. Participants will re...

Sacramento, CAPHASE115 participantsCellio Therapeutics Inc

View Study Details

About Geographic Atrophy Clinical Trials in Sacramento

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 13 geographic atrophy clinical trials recruiting participants in Sacramento, CA. These studies are seeking a combined 14,900 participants. Research is being sponsored by Genzyme, a Sanofi Company, University of Calgary, AstraZeneca and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Sacramento — FAQ

Are there geographic atrophy clinical trials in Sacramento?

Yes, there are 13 geographic atrophy clinical trials currently recruiting in Sacramento, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Sacramento?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you about next steps.

Are clinical trials in Sacramento free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sacramento studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 13 active trials in Sacramento are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated October 15, 2026 from ClinicalTrials.gov